%0 Journal Article
%A Schmitz, Matthias
%A Canaslan, Sezgi
%A Espinosa, Juan Carlos
%A Fernández-Borges, Natalia
%A Villar-Piqué, Anna
%A Llorens, Franc
%A Varges, Daniela
%A Maass, Fabian
%A Torres, Juan Maria
%A Hermann, Peter
%A Zerr, Inga
%T Validation of Plasma and CSF Neurofilament Light Chain as an Early Marker for Sporadic Creutzfeldt-Jakob Disease.
%J Molecular neurobiology
%V 59
%N 9
%@ 0893-7648
%C Totowa, NJ
%I Humana Press
%M DZNE-2022-01300
%P 1-9
%D 2022
%X Biomarkers are becoming increasingly important for the differential diagnosis of neurodegenerative diseases. Previous observations indicated neurofilament light chain (NfL) as a potential blood-based biomarker for sporadic Creutzfeldt-Jakob disease (sCJD). Here, we investigated the stability, inter-assay/intra-assay variation and the regulation of NfL levels in CSF and plasma in a large cohort of sCJD patients by using a single-molecule array (SIMOA). We defined cutoffs for an accurate diagnosis and measured plasma NfL level in prion-infected mice models at different time points to identify the potential dynamics throughout the disease. Our analyses confirmed CSF and plasma NfL as stable and consistent marker for sCJD. Receiver operating characteristic (ROC) curve analysis showed an AUC of 0.92-0.93 to distinguish sCJD from control groups. Newly defined cutoffs revealed good diagnostic accuracies of CSF and plasma NfL, indicated by a sensitivity of 80-83.5
%K Animals
%K Biomarkers
%K Creutzfeldt-Jakob Syndrome: diagnosis
%K Humans
%K Intermediate Filaments
%K Mice
%K Neurofilament Proteins
%K Prions
%K tau Proteins
%K Biomarkers (Other)
%K Diagnostic (Other)
%K Neurofilament light chain (Other)
%K Plasma (Other)
%K Sporadic Creutzfeldt-Jakob disease (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:35716271
%R 10.1007/s12035-022-02891-7
%U https://pub.dzne.de/record/164856